Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. - Wikidata - wikimedia - TriplyDB

Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.

Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.

http://www.wikidata.org/entity/Q33681753

about

Overview of the Diagnostic Methods Used in the Field for Human African Trypanosomiasis: What Could Change in the Next Years?Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis Trypanothione reductase: a target protein for a combined in vitro and in silico screening approach Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review Performance of the SD BIOLINE® HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the Congo Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease Monitoring the Progress towards the Elimination of Gambiense Human African Trypanosomiasis.We Remember… Elders' Memories and Perceptions of Sleeping Sickness Control Interventions in West Nile, Uganda A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections Treatment options for second-stage gambiense human African trypanosomiasis.Integration of diagnosis and treatment of sleeping sickness in primary healthcare facilities in the Democratic Republic of the Congo.A DBS method for quantitation of the new oral trypanocidal drug fexinidazole and its active metabolites.Future treatment options for human African trypanosomiasis.Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon.Heterogeneity in the in vitro susceptibility of Loa loa microfilariae to drugs commonly used in parasitological infections.Prospective evaluation of a rapid diagnostic test for Trypanosoma brucei gambiense infection developed using recombinant antigens.Novel lead compounds in pre-clinical development against African sleeping sickness

P2860

Q26778571-BB40B93A-9FF5-496F-B92C-9E59AE6BE8FC Q27011766-B37375DB-5930-4E98-ABBC-E0B25BE876D9 Q28547882-64373ACF-C973-420F-8F35-F09BF82FEC60 Q28550224-32A4EE3D-9682-4114-A580-86B93E885768 Q33658786-91C7E3A1-3384-4BE6-9E8B-FC2BF4B19C83 Q33866223-F3A8274A-99D1-410E-8ACD-03C514A91B6A Q34058185-FB705255-BD40-4965-8338-A2D27DE18297 Q35657780-75C34282-9933-40F2-979D-3F5F41C850D6 Q36037787-392C51CA-E9FF-47D4-936B-FE234FD8FFD3 Q36311615-C2F7B7BE-E760-4683-84D4-09E1A45529B0 Q36551049-F1F1640F-20FC-487A-9F1B-DE27D3E99D0E Q39254761-AEA10BA5-E34C-41F8-A9F5-C8697CA912A2 Q46268194-CCE8B554-04DB-4968-9CAA-EC99C8B6B097 Q48373153-AACB8B45-6027-4332-B1EF-EA86C6FAAA12 Q49596380-37F4B1E0-0306-4A8F-B101-EB032E8E9B6C Q52609400-642AB74E-AE42-4774-827B-07ABDC84367D Q52625675-FC64599C-3A9C-4309-8036-CADD211CC299 Q58842335-40400251-23D9-4A04-8699-D5D7B5F455CB

P2860

Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.

http://www.wikidata.org/entity/Q33681753

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Determination of an optimal do ...... iasis: first-in-human studies.

@ast

Determination of an optimal do ...... iasis: first-in-human studies.

@en

type

label

Determination of an optimal do ...... iasis: first-in-human studies.

@ast

Determination of an optimal do ...... iasis: first-in-human studies.

@en

prefLabel

Determination of an optimal do ...... iasis: first-in-human studies.

@ast

Determination of an optimal do ...... iasis: first-in-human studies.

@en

P1433

Q33681753-E4C30A0E-03E0-41B1-B752-AF9A755DD66F

P1476

Q33681753-5D2A1D23-1990-40F5-8031-AF0A83D2EF02

P2093

Q33681753-0CC12180-291F-4957-BE6B-12513613C08A

Q33681753-1A1C12DA-52D1-4840-95BC-A8AF15D32109

Q33681753-285DC6F8-BAFA-4D84-9E91-801EE7C20EFD

Q33681753-2E7B3A06-5E8F-460D-AD3B-010211FD5B1A

Q33681753-43D5325A-E107-4A40-9A14-787EF3FAB277

Q33681753-806932B1-19C3-418A-8C7F-3D08D0D01E73

Q33681753-82E064F7-9600-4DCC-BA3E-DDA1AAED07FD

Q33681753-97B40437-95B2-4EFB-8510-2A468DA6E563

Q33681753-F0D2B4DB-39FF-4F03-8581-A92596091174

Q33681753-FC31F161-CB00-4498-82F6-011EA10BDA69

P2860

Q33681753-09AD58CC-0CCC-4846-A7F4-9769C70DB7ED

Q33681753-1109A005-1CBA-47AA-9FE8-10E57426D0C1

Q33681753-11458658-7A8F-496A-9944-FD4E8848B30C

Q33681753-14BBCD2F-E032-4BE4-917F-AEEBFFE06816

Q33681753-156D4F8D-82B8-4E2F-B855-384D656DB0A4

Q33681753-179EF866-02C4-4A69-9618-6E4BA8B1DA3A

Q33681753-21B83601-751F-4060-B32D-633FB0708A09

Q33681753-32287616-3F36-4FCE-8C4A-57F8952FACE6

Q33681753-365330B4-CDBE-4C46-8DC1-65284F6F4F16

Q33681753-43CD6991-BD18-481C-826A-17DDD53813F1

P2888

Q33681753-7EED8CB6-E5F9-41C3-9868-9F07A8F60259

P304

Q33681753-84D84E4B-830C-43CC-A4A3-2B5DD8AF03FA

P31

Q33681753-9487FE2F-B716-42D6-B2A3-3F5F6ED8D12A

P356

Q33681753-BCC7F6DB-E6BD-4069-8862-D5C7C3B9D312

P433

Q33681753-51D44C36-1D8A-411A-947F-044BB8B0446C

P478

Q33681753-84D01449-15EE-4669-BD39-7380C67E8DF9

P50

Q33681753-AB32B56A-C4B2-4BFE-A080-1DAE6F9413B7

P577

Q33681753-AA749788-5EAD-4F44-B781-AEFA2A80AFF8

P5875

Q33681753-71BECFFA-08F9-49B8-AE7D-59D8352D9A62

P6179

Q33681753-3A97E247-3400-47F3-9F4B-8920C96CA230

P698

Q33681753-DC4EF3ED-6526-4A37-A96D-9A8F32FB52D7

P921

Q33681753-754B635E-6215-4FE8-BF7D-58030581B23F

Q33681753-8BC9469A-72B3-46BE-9358-E89BAF73B2D0

Q33681753-AE797947-5E7C-40E3-A0F6-72C32700DD51

P932

Q33681753-3DC28C1E-1E34-4492-B1E3-27F48FD98ECE

P356

S40262-014-0136-3

P1433

Clinical Pharmacokinetics

P1476

Determination of an optimal do ...... iasis: first-in-human studies.

@en

P2093

Antoine Tarral

http://www.w3.org/2001/XMLSchema#string

Daniela Sassella

http://www.w3.org/2001/XMLSchema#string

Els Torreele

http://www.w3.org/2001/XMLSchema#string

Eric Evène

http://www.w3.org/2001/XMLSchema#string

Lionel Hovsepian

http://www.w3.org/2001/XMLSchema#string

Mathieu Felices

http://www.w3.org/2001/XMLSchema#string

Michael A Bray

http://www.w3.org/2001/XMLSchema#string

Nathalie Strub-Wourgaft

http://www.w3.org/2001/XMLSchema#string

Olaf Valverde Mordt

http://www.w3.org/2001/XMLSchema#string

Virginie Gualano

http://www.w3.org/2001/XMLSchema#string

P2860

Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness

The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

Fexinidazole: a potential new drug candidate for Chagas disease

Human African Trypanosomiasis in the Democratic Republic of the Congo: A Looming Emergency?

Transaminase elevation on placebo during phase I trials: prevalence and significance.

Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.

In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.

P2888

s40262-014-0136-3

P304

565-580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-014-0136-3

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Séverine Blesson

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260242425

http://www.w3.org/2001/XMLSchema#string

P6179

1028584058

http://www.w3.org/2001/XMLSchema#string

P698

24535888

http://www.w3.org/2001/XMLSchema#string

P921

African trypanosomiasis

trypanosomiasis

P932

4037587

http://www.w3.org/2001/XMLSchema#string